<DOC>
	<DOCNO>NCT00777400</DOCNO>
	<brief_summary>The purpose pilot trial determine whether conversion calcineurin inhibitor ( CNI ) mycophenolate mofetil ( MMF ) regimen consist efalizumab sirolimus associate increase T regulatory cell , white cell control immune system prevent autoimmune disease like arthritis rejection foreign organ , result increase acute rejection .</brief_summary>
	<brief_title>Pilot Trial Assess Effect CNI Conversion Efalizumab T Reg Cells</brief_title>
	<detailed_description>The objective pilot trial determine whether conversion calcineurin inhibitor ( CNI ) mycophenolate mofetil ( MMF ) efalizumab sirolimus associate increase T regulatory cell result increase acute rejection follow conversion . CNIs associate progressive nephrotoxicity , increase cardiovascular risk factor well inhibitory effect T regulatory cell . PRIMARY OBJECTIVE : To determine combination efalizumab sirolimus result significant increase T regulatory cell . A hundred percent increase T regulatory cell determine important biologic effect combination efalizumab sirolimus . SECONDARY OBJECTIVES : To assess feasibility conversion CNI/MMF efalizumab/sirolimus determine combination safe effective To determine increase FoxP3 mRNA urine convert patient . Urine FoxP3 believe correlate T regs kidney .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study . Male female , 1870 year Recipients primary renal transplant live deceased donor Stable renal function 4 week prior entry study No history acute rejection Pretransplant negative crossmatch Hematocrit &gt; 30 % time inclusion , platelet count &gt; 100,000 WBC ≥ 3.0 If female childbearing potential , negative pregnancy test commitment use two form effective contraception ( birth control ) duration study necessary . If nonsterile male , commitment use two form effective contraception ( birth control ) duration study necessary . Patients know hypersensitivity Raptiva® ( efalizumab ) component . Pregnant lactate woman Pretransplant PRA &gt; 20 % cGFR &lt; 35/ml/min &gt; 500 mg protein estimate spot protein/creatinine ratio Recipients organ transplant Subject current malignancy history malignancy , except nonmetastatic basal squamous cell carcinoma skin treat successfully . Patients receive experimental immunosuppressive agent Prior enrollment study Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Participation another simultaneous medical investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Kidney transplant</keyword>
	<keyword>T regulatory cell</keyword>
	<keyword>Efalizumab</keyword>
	<keyword>Rejection</keyword>
	<keyword>Safely convert renal transplant mycophenolate mofetil Calcineurin inhibitor efalizumab sirolimus</keyword>
</DOC>